Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Dysautonomias 1Pancreatic Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1High Risk Prostate Cancer 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Receptors, Androgen × Clear all
NCT05700903 2026-03-02

ARCH

University of Colorado, Denver

Phase 4 Completed
10 enrolled
Genitourinary

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT06758882 2025-01-06

STAPLE

A.O.U. Città della Salute e della Scienza

Phase 2 Recruiting
94 enrolled
Genitourinary

High Risk Prostate Cancer

NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
25 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡